Advertisement

Picture EBD Group BIO-Europe 2021 Digital BEU2021 650x80
All >

Deals > Southern Europe & Israel

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Southern Europe & Israel or involving organisations from these regions.

Total search results: 402 | Ordered by Date (descending)
1 2 3 4 5  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Biotest–Grifols: investment, 202109– public cash tender offer €895m for remaining 54.5% of shares at €34/ordinary share + €37/preferred share 2021-09-17
Creat (CN)–Grifols: investment, 202109 acquisition 100% of Tiancheng Germany owning 90% voting rights + 45% total capital of Biotest for €773m cash 2021-09-17
Claris Ventures–EU (govt): investment, 202107 final closing of Claris Biotech I funds totalling €85m incl €40m from EIF 2021-07-21
Claris Ventures–Italy (govt): investment, 202107 final closing of Claris Biotech I funds totalling €85m incl CDP Venture Capital on behalf of clients 2021-07-21
Claris Ventures–SEVERAL: investment, 202107 final closing of €85m Claris Biotech I funds led by EIF + incl CDP Venture Capital 2021-07-21
Panakès Partners–EU (govt): investment, 202107 first closing totalling €150m of Purple Fund incl co-lead investor EIF 2021-07-20
Panakès Partners–Italy (govt): investment, 202107 first closing totalling €150m of Purple Fund incl co-lead investor CDP Venture Capital FoF 2021-07-20
Panakès Partners–SEVERAL: investment, 202107 first closing €150m of Purple Fund 2021-07-20
Nerre Therapeutics–Columbus Venture Partners: investment, 202107 financing round Series B2 totalling £20m incl new + lead investor Columbus VP 2021-07-07
Merck (DE)–Nucleai MD: AI-based biomarker discovery, 202106– long-term collab using ATOM platform for cancer biomarker discovery 2021-06-24
Kahr-Medical–aMoon: investment, 202106 financing round totalling $46.5m incl lead investor aMoon 2021-06-16
Kahr-Medical–BVF Partners: investment, 202106 financing round totalling $46.5m incl new + co-investor BVF Partners LP 2021-06-16
Kahr-Medical–Cancer Focus Fund: investment, 202106 financing round totalling $46.5m incl new + co-investor Cancer Focus Fund 2021-06-16
Kahr-Medical–Dafna Capital: investment, 202106 financing round totalling $46.5m incl new + co-investor Dafna Capital Management LLC 2021-06-16
Kahr-Medical–Flerie Invest: investment, 202106 financing round totalling $46.5m incl existing + co-investor Flerie Invest AB 2021-06-16
Kahr-Medical–Hadasit Bio-Holdings: investment, 202106 financing round totalling $46.5m incl existing + co-investor Hadasit Bio Holdings Ltd 2021-06-16
Kahr-Medical–Mirae Asset: investment, 202106 financing round totalling $46.5m incl existing + co-investor Mirae Asset 2021-06-16
Kahr-Medical–Oriella: investment, 202106 financing round totalling $46.5m incl existing + co-investor Oriella Ltd 2021-06-16
Kahr-Medical–Pavilion Capital: investment, 202106 financing round totalling $46.5m incl existing + co-investor Pavilion Capital 2021-06-16
Kahr-Medical–Peregrine Ventures: investment, 202106 financing round totalling $46.5m incl new + co-investor Peregrine Ventures 2021-06-16
Kahr-Medical–SEVERAL: investment, 202106 financing round $46.5m led by aMoon 2021-06-16
Kahr-Medical–Shavit Capital: investment, 202106 financing round totalling $46.5m incl new + co-investor Chavit Capital 2021-06-16
ViveBiotech–Image Box: public relations, 202106 service existent by Image Box Communications 2021-06-04
Highlight Therapeutics–Droia Ventures: investment, 202105 existent portfolio company of Droia 2021-05-17
Cytoki Pharma–Ysios Capital: investment, 202105 financing round Series A totalling $45m incl co-investor Ysios Capital 2021-05-05
Adcendo–Ysios Capital: investment, 202104 financing round Series A totalling €51m incl co-lead investor Ysios Capital 2021-04-29
Synendos Therapeutics–Ysios Capital: investment, 202104 investment by new investor Ysios Capital extends financing round Series A to CHF24m 2021-04-20
Luminex–DiaSorin: investment, 202104– acquisition $1.8b in cash for $37/share by DiaSorin ANNOUNCED 2021-04-11
Nucleix–SEVERAL: investment, 202104 financing round $55m led by RA Capital Management 2021-04-07
Nucleix–UDG Healthcare: public relations, 202104 service existent by Canale Communciations 2021-04-07
Inbrain Neuroelectronics–SEVERAL: investment, 202006 seed financing round led by Sabadell-Asabys + Alta Life Sciences 2021-03-26
Inbrain Neuroelectronics–SEVERAL: investment, 202103 financing round Series A €14.35m led by Asabys Partners incl follow-on from ICF VTII 2021-03-26
Dropprint Genomics––Immunai: investment, 202103 acquisition of Dropprint Genomics by Immunai 2021-03-25
Scipher Medicine–aMoon: investment, 202103 financing round Series C totalling $82m incl co-lead investor aMoon 2021-03-24
Step Pharma–Pontifax: investment, 202103 financing round Series B totalling €35m incl existing + co-investor Pontifax 2021-03-24
AgomAb Therapeutics–Pontifax: investment, 202103 financing round Series B totalling $74m incl existing + co-investor Pontifax 2021-03-10
Biolojic Design–Burns McClellan: public relations, 202103 service existent Burns McClellan is media contact 2021-03-08
Lilly–Biolojic Design: antidiabetic antibodies, 202103– collab AI-based discovery + developm of antibody therapies for diabetes 2021-03-08
Almirall–MC2 Therapeutics: Wynzora Cream, 202102– license excl to commercialise Wynzora Cream for plaque psoriasis in Europe for Almirall 2021-02-17
Immunai–Dexcel Pharma: investment, 202102 financing round Series A totalling $60m incl new + co-lead investor Dexcel Pharma 2021-02-11
BiondVax–SEVERAL: investment, 202101– Public Offering $12m+$1.8m with 2.4m+365k ADSs at $4.95/ADS 2021-01-28
Enthera–Roche: investment, 202101 financing round Series A extension to final closing at €35m with new investor Roche Venture Fund 2021-01-28
Minoryx–Image Box: public relations, 202101 service existent by Image Box Communications 2021-01-26
Omnix Medical–EU (govt): grant, 202101– funding €10.8m under EIC Accelerator Programme to advance antibiotic OMN6 2021-01-25
TScan Therapeutics–Pitango: investment, 202101 financing round Series C totalling $100m incl existing investor Pitango HealthTech 2021-01-25
Sanofi–Biond Biologics: antibody cancer drug, 202101– license ww excl to BND-22 anti-IgG4 antibody $125m upfront + >$1b milestones + royalties 2021-01-12
CorWave–Ysios Capital: investment, 202101 financing round Series C totalling €35m incl existing + co-investor Ysios Capital 2021-01-06
Peptilogics–Angermayer Group: investment, 202012 financing round Series B totalling $35.4m incl new + lead investor Presight Capital 2020-12-21
Galapagos–Selvita: drug discovery services, 202011– 202512 supply for 5y by Fidelta after sale by Galapgaos to Selvita 2020-11-23
Galapagos–Selvita: investment, 202011– acquisition 100% of Fidelta d.o.o. for €31.2m in cash by Selvita SA 2020-11-23
Omnix Medical–SEVERAL: investment, 202011 financing round $8.5m co-led by Tal Capital + Entrée Capital + CBG Group 2020-11-20
SparingVision–Ysios Capital: investment, 202010 financing round totalling €44.5m incl new + co-investor Ysios Capital 2020-10-21
Sensei Biotherapeutics–Angermayer Group: investment, 202010 financing round Series A totalling $28.5m incl new + co-investor Apeiron Investment Group 2020-10-07
BIA Separations–Sartorius: investment, 202010– acquisition €240m in cash + €120m in SSB shares BIA to be merged into SSB ANNOUNCED 2020-10-02
Sophia Genetics–aMoon: investment, 202010 financing round Series F totalling $110m incl co-lead investor aMoon 2020-10-01
Wise (IT)–SEVERAL: investment, 202010 financing round Series C €15m led by CDP Venture Capital SGR 2020-10-01
Prolytic–Kymos: investment, 202009 strategic merger of Polytic GmbH + Kymos SL 2020-09-28
Salvia BioElectronics–Panakès Partners: investment, 202009 financing round Series A totalling €21m incl new + co-lead investor Panakès Partners 2020-09-22
Lava Therapeutics–Ysios Capital: investment, 202009 financing round Series C totalling $83m incl new + co-investor Ysios Capital 2020-09-17
Neogene Therapeutics–Pontifax: investment, 202009 financing round Series A totalling $110m incl new + co-investor Pontifax 2020-09-14
MiNA Therapeutics–aMoon: investment, 202009 financing round Series A totalling £23m ($30m) incl new + lead investor aMoon 2020-09-10
Algenex–SEVERAL: investment, 202009 private financing round €7.4m led by MasterLux + incl new investor Columbuus Life Science Fund II 2020-09-08
Genespire–Consilium: public relations, 202007 service existent by CSC 2020-07-30
Enthera–AbbVie: investment, 202007 financing round Series A totalling €28m incl new + co-lead investor AbbVie Ventures 2020-07-28
Enthera–Banca Profilo: investment, 202007 financing round Series A totalling €28m incl new + co-investor group co-ordinated by Arepo Fiduciaria 2020-07-28
Enthera–Banor SIM: investment, 202007 financing round Series A totalling €28m incl new + co-investor group co-ordinated by Banor SIM 2020-07-28
Enthera–Indaco Venture Partners: investment, 202007 financing round Series A totalling €28m incl new + co-investor Indaco Venture Partners SGR 2020-07-28
Enthera–Instinctif Partners: public relations, 202007 service existent by Instinctif 2020-07-28
Enthera–Juvenile Diabetes Research Foundation: investment, 202007 financing round Series A totalling €28m incl existing + co-investor JDRF T1D Fund 2020-07-28
Enthera–SEVERAL: investment, 202007 financing round Series A €28m co-led by Sofinnova Partners + AbbVie Ventures 2020-07-28
Enthera–Sofinnova: investment, 202007 financing round Series A totalling €28m incl existing + co-lead investor Sofinnova Partners 2020-07-28
Optimapharm–Coulter Partners: recruitment services, 202007 supply service placement of Andrew Copestake as CEO at Optimapharm 2020-07-28
Lysogene–Weizmann Institute: gene therapy, 202007– collab research + license option AAV gene therapy for Gaucher + Parkinson diseases 2020-07-01
Enterome–Principia SGR: investment, 202006 financing round Series E €na incl existing investor Principia 2020-06-25
Ona Therapeutics–Alta Life Sciences: investment, 202006 financing round Series A totalling €30m incl new investor Alta Life Sciences 2020-06-16
Ona Therapeutics–Asabys Partners: investment, 202006 financing round Series A totalling €30m incl existing investor Sabadell Asabys 2020-06-16
Ona Therapeutics–France (govt): investment, 202006 financing round Series A totalling €30m incl new investor Bpifrance InnoBio 2 2020-06-16
Ona Therapeutics–Fund+: investment, 202006 financing round Series A totalling €30m incl new investor Fund+ 2020-06-16
Ona Therapeutics–Optimum Strategic Communications: public relations, 202006 service existent by Optimum 2020-06-16
Ona Therapeutics–SEVERAL: investment, 202006 financing round Series A €30m 2020-06-16
Ona Therapeutics–Ysios Capital: investment, 202006 financing round Series A totalling €30m incl new investor Ysios Capital 2020-06-16
Epsilen Bio–Sofinnova: investment, 202006c seed financing €2.3m from Sofinnova Partners through Sofinnova Telethon Fund 2020-06-15
Ysios Capital–SEVERAL: investment, 202006 first closing €155m of Ysios BioFund III with target size of €200m 2020-06-10
Rigenerand–Image Box: public relations, 202005– supply service by Image Box PR 2020-05-29
Accure Therapeutics–SEVERAL: investment, 202005 financing round Series A €7.6m led by Alta Life Sciences with support from CDTI 2020-05-26
Genespire–San Raffaele: gene therapy, 2002005– collab strategic alliance development of gene therapies with SR-Tiget 2020-05-13
Optimapharm–TRG Management: investment, 202005 investment by The Rohatyn Group to grow organically + via acquisitions 2020-05-12
ElsaLys–Mediolanum: investment, 202005 acquisition of ElsaLys Biotech by Mediolanum Farmaceutici SpA 2020-05-07
Pluristem–Dentons: legal services, 202005 supply service Dentons is adivsor with regard to €50m EIB loan financing 2020-05-05
Stemline Therapeutics–Menarini: investment, 202005– acquisition up to $677m ANNOUNCED 2020-05-04
PinCell–SEVERAL: investment, 202004 seed financing round €1.65m led by Sofinnova Telethon Fund 2020-04-30
PinCell–Sofinnova: investment, 202004 seed financing round totalling €1.65m incl lead investor Sofinnova Telethon Fund 2020-04-30
Genespire–Sofinnova: investment, 202004 Series A financing €16m from Sofinnova Partners 2020-04-29
LNC Therapeutics–Univ Valencia: microbiomic treatment, 202004– license ww excl for patent on Christensenella therapeutics for mood disorders 2020-04-15
Axxam–ERS Genomics: CRISPR technology, 202004– license ww €na for drug discovery services of Axxam 2020-04-02
MolMed–Asahi Glass: investment, 202003– cash tender offer €240m for 463.5m shares at €0.518/share by AGC Inc ANNOUNCED 2020-03-17
Autolus–MolMed: viral vectors, 202003– collab multi-year developm + supply of viral vectors by MolMed for T cell cancer therapies 2020-03-05
BIA Separations–Univ Zagreb: purification technology, 202002– commercial license + collab developm of virus + viral vector immunoaffinity purification 2020-02-19
Almirall–23andMe: therapeutic antibodies, 202001– license ww to bispecific MAb blocking all 3 isoforms of IL-36 2020-01-09
Almirall–WuXi PharmaTech: therapeutic antibodies, 202001– collab strategic r+d bispecific Abs for dermatology using WuXiBody antibody technology 2020-01-09
1 2 3 4 5  next pagenext page



Advertisement

Picture EBD Group Connector Personal Networking in Life Sciences 650x80

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Advertisement

Picture Demy-Colton BioFuture 2021 NYC E Hand 650x300px

» top